EN DE
Watch Elevai Labs, Inc. for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Elevai Labs, Inc. (ELAB) fair value: what the stock is really worth

As of Nov 18, 2026: fair value (intrinsic value) of Elevai Labs, Inc. stock $1.93, price $1.47, upside +31.3%, quality 19 out of 100. Rating: undervalued. Calculated from audited financials with one of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

EL Elevai Labs, Inc. logo Thin data Nov 16, 2026

Elevai Labs, Inc.

ELAB · US

Cheap (24% below fair value), but weak company and falling price: meets 1 of 3 rules.

Follow free in the weekly email
Fair value $1.93 · Undervalued 
Recent news very positive 
Mixed vs. peers (3/7) 
Revenue last quarter 46% below a year ago. 
Quality 19/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −8.3 %/yr in USD) 
Negative free cash flow 
Narrow moat 3/100 · thin data
Thin data 
⚠ Dilution
Watch Elevai Labs, Inc. for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$1,000,000 $1.47 Fair Value $1.93 Nov 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

36‑month range $1.47 – $1,000,000 · fair‑value band $1.28 – $2.41 · the $1.47 price screens below the $1.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Elevai Labs in your weekly email

Every Wednesday you see whether Elevai Labs is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

PMGC Holdings Inc., a biopharmaceutical company, focuses on the development and acquisition of aesthetic medicines and therapeutic products. It operates through three segments: corporate, treasury and biosciences; IT packaging solutions; and precision engineering and machining.

Show moreShow less

The company's lead product includes EL-22, a first-in-class engineered probiotic approach to address obesity's pressing issue of preserving muscle while on weight loss treatments, including GLP-1 receptor agonists.

It is also involved in the medical scientific research and development activities, as well as operating investment firms; providing packaging solutions to industrial and consumer markets; and design and production of high-tolerance components for industrial and technological applications.

The company was formerly known as Elevai Labs, Inc. and changed its name to PMGC Holdings Inc. in December 2024. PMGC Holdings Inc. was incorporated in 2020 and is based in Newport Beach, California.

Stock analysis

Elevai Labs, Inc. (ELAB) currently trades at $1.47, while our model-based Fair Value estimate is $1.93, implying the stock looks roughly 24% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.

Scenario range: $1.28 (bear) to $2.41 (bull), the price of $1.47 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Elevai Labs, Inc. reported revenue of $590K in FY2025 versus $827 in FY2021, a compound +416.8%/yr. Reported net income was −$7.7M in FY2025.

Key figures

Market cap $1.1M Micro · P/S ratio 0.50 · EPS (TTM) $−1,748 · Return on equity −105% · Return on assets (EBIT) −62.5% (5-year average) · Operating margin −470% · Revenue growth (YoY) −45.8% · Free cash flow −$6.4M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 3 out of 100 (low confidence).

What moves the price

The share trades about 100% below its 52-week high and at its 52-week low.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at 31%, ELAB screens cheaper than that median.

Fair Value models

Bear $1.28 Fair Value $1.93 Bull $2.41
Price $1.47 · Upside +31.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $1.50 $2.27 $2.84 52
All 1 models by family
Asset-Based
NCAV (Graham) $1.50 $2.27 $2.84 52

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 19/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 20
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 50
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 0
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−76.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−94,928.7% (2021) → −1,250.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ELAB, get fair value alerts →

Recent news

News mood ⓘNews mood, the average tone of recent news (69 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.

Compare Elevai Labs, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside +31.3% · Top 25%
Profitability
Return on assets −59.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −45.8% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 0.14× · Cheapest 25%
P/S (12 months) 0.44× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)75 · sector 2
FUTURE (revenue growth)0 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $945.53 $1,275 +35% vs ELAB
Vertex Pharmaceuticals Incorporated VRTX $536.45 $587.62 +10% vs ELAB
Samsung Biologics Co 207940 1,375,000 KRW 1,502,600 KRW +9% vs ELAB
argenx SE ARGX $941.25 $908.40 −3% vs ELAB
CSL Limited CSL A$199.85 A$186.49 −7% vs ELAB
Moderna, Inc MRNA $196.79 $135.64 −31% vs ELAB
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs ELAB
Revolution Medicines, Inc RVMD $159.82 $83.12 −48% vs ELAB
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs ELAB
Royalty Pharma plc RPRX $68.67 $19.01 −72% vs ELAB

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Elevai Labs, Inc.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Elevai Labs, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/ELAB

Frequently asked questions

Is Elevai Labs, Inc. (ELAB) overvalued or undervalued?
As of Nov 16, 2026, our model estimates a fair value of $1.93 versus a price of $1.47, about +31% upside (undervalued).
What is the fair value of ELAB?
Our model-based fair value for Elevai Labs, Inc. is $1.93 (as of Nov 16, 2026), built from audited fundamentals. The current price: $1.47.
What is the quality score of ELAB?
Elevai Labs, Inc. has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Elevai Labs, Inc. (ELAB)?
We do not set a price target; the yardstick is the fair value of $1.93 (as of Nov 16, 2026) from 1 valuation models. Cautious scenario $1.28, optimistic scenario $2.41. It is a calculation from audited fundamentals, not an analyst target.
What is the Elevai Labs, Inc. stock forecast for 2026?
Our models put fair value at $1.93, about +31% upside versus a price of $1.47 (undervalued). Cautious scenario $1.28, optimistic scenario $2.41. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Elevai Labs, Inc. (ELAB)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Elevai Labs, Inc. it is $1.93 per share (as of Nov 16, 2026), against a price of $1.47. It is the blended result of 1 valuation models in 1 family (Asset-Based).
Is Elevai Labs, Inc. stock overvalued or undervalued in 2026?
As of Nov 16, 2026, ELAB trades below its calculated fair value: price $1.47, fair value $1.93, a gap of about +31% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ELAB?
No. The price is what the market pays today ($1.47); the fair value is what the company's own numbers justify ($1.93). For Elevai Labs, Inc. the two are $0.4595 per share apart. That gap is exactly why we show both numbers side by side.
How much is Elevai Labs, Inc. worth?
The market values Elevai Labs, Inc. at about $1.1M (market capitalisation, as of Nov 16, 2026). Per share that is $1.47; our models calculate a fair value of $1.93 per share.
What do the bullish and bearish scenarios say about ELAB?
Our models span a range for Elevai Labs, Inc.: cautious scenario $1.28, base $1.93, optimistic $2.41 per share (as of Nov 16, 2026, price $1.47). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Elevai Labs, Inc. (ELAB)?
Balance-sheet figures for Elevai Labs, Inc. (as of Nov 16, 2026): return on equity −105.2%. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is ELAB from its 52-week high?
Elevai Labs, Inc. trades at $1.47, about 100% below its 52-week high of $1,291 and at the low of $1.47 (as of Nov 18, 2026). Distance from the high says nothing about value: that is what the fair value of $1.93 is for.
Which stocks are comparable to Elevai Labs, Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Elevai Labs, Inc. stock attractive at the current price?
The data as of Nov 16, 2026: price $1.47, calculated fair value $1.93 (+31%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ELAB calculated?
We run Elevai Labs, Inc. through 1 models from 1 family: Asset-Based. Every model gets the same audited fundamentals; the fair value of $1.93 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Elevai Labs, Inc. currently trades 24% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Elevai Labs, Inc. (ELAB)?
The closing price on Nov 18, 2026 was $1.47. Our model-based fair value is $1.93, about +31% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Elevai Labs, Inc. right now?
The large discount to fair value meets weak quality (19/100). That raises the risk this is a value trap rather than a bargain. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($1.28 to $2.41) leaves room in how you read the outcome.

Key figures of Elevai Labs, Inc.

How large is the market capitalisation of Elevai Labs, Inc. (ELAB)?
The market capitalisation of Elevai Labs, Inc. is $1.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Elevai Labs, Inc. (ELAB)?
The price-to-sales ratio of Elevai Labs, Inc. is 0.50 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Elevai Labs, Inc. (ELAB)?
Earnings per share at Elevai Labs, Inc. are $−1,748. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Elevai Labs, Inc. (ELAB)?
The return on equity (ROE) of Elevai Labs, Inc. is −105% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Elevai Labs, Inc. (ELAB)?
On an EBIT basis the return on assets of Elevai Labs, Inc. is −62.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Elevai Labs, Inc. (ELAB)?
The operating margin of Elevai Labs, Inc. is −470% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Elevai Labs, Inc. (ELAB)?
Revenue at Elevai Labs, Inc. is down 45.8% versus a year earlier (3y avg −8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Elevai Labs, Inc. (ELAB) generate?
The free cash flow of Elevai Labs, Inc. is −$6.4M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Elevai Labs, Inc. (ELAB) hold?
Elevai Labs, Inc. holds more cash than debt, $2.8M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Elevai Labs, Inc. in the live analysis

One click puts Elevai Labs, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.